The guidance documents of #EUPATI on the interaction of patient organisations and other stakeholders in the medicines development process has been one of the key outcomes of the original EUPATI project under Innovative Medicines Initiative.
Developed as a consensus of a rigorous team composed of all stakeholders (academia, regulators, patient organisations, industry), these guidance documents give recommendations and practical advice on how to work with patients in a meaningful way.
The first webinar in a series of four that discuss these guidance documents was held on 04/05/2017. The topic was the interaction of patient organisations and industry. It was hugely oversubscribed and very well attended, and featured presentations by EUPATI UK NLT member Kay Warner of GSK, Prof. Ingrid Klingmann from EFGCP, Prof. Wolf See from EMTRAIN, and David Haerry from the European AIDS Treatment Group.
Please watch and share widely. #patientsinvolved